Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank

11 Sept 2023

Abstract excerpt

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly. CYP2C19 is a key enzyme involved in the metabolism of several drugs, including SSRIs. Variations in the CYP2C19 gene are associated with differential metabolic activity, and thus differential SSRI exposure; accordingly, the...

Source

Identifiers

PMID: 37765085
DOI: 10.3390/ph16091277

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK BiobankPMID 37765085Read ↗

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.Semantic proximity Read ↗

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting.Semantic proximity Read ↗

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression StudySemantic proximity Read ↗

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studiesSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.Semantic proximity Read ↗

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.Semantic proximity Read ↗

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputationSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort StudySemantic proximity Read ↗

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.Semantic proximity Read ↗

Genotyping of patients treated with selective serotonin reuptake inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.